Signal Genetics Plans to Release Pharmacogenomic Version of Myeloma Test Later This Year
June 01, 2011
Signal Genetics Plans to Release Pharmacogenomic Version of Myeloma Test Later This Year
The company plans two new versions of its MyPRS test later this year, including a pharmacogenomic enhancement called MyPRS RX and a version called MyPRS Plus that will perform myeloma subgroup analysis.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Signal Genetics Taps NeoGenomics to Market Array-Based Myeloma Test to US Hospitals
May 31, 2011 / BioArray News - Prospective Validation Confirms Sensitivity of Veracyte's Gene Expression Test for Thyroid Nodule Risk
June 27, 2012 / Pharmacogenomics Reporter - GeneKey Sees Breadth of Cancer Genome Advisory Service as Differentiator in Rapidly Growing Market
December 21, 2011 / Pharmacogenomics Reporter - UPDATE: Signal Genetics Makes Improved Offer to Market Med BioGene Test
March 23, 2011 / GenomeWeb Daily News - Caris to Offer Signal Genetics' Multiple Myeloma Profiling Test
January 5, 2011 / GenomeWeb Daily News